Market Research Report
Global Intravenous Immunoglobulin Market - 2020-2027
|Global Intravenous Immunoglobulin Market - 2020-2027|
Published: May 10, 2021
Content info: 180 Pages
Delivery time: 2 business days
Immunoglobulin refers to the breakdown of blood plasma that contains antibodies. Intravenous immunoglobulin (IVIG) is defined as a blood product administered intravenously. This therapy is for individuals who cannot produce an adequate number of antibodies. Intravenous immunoglobulin therapy treats patients with common variable immunodeficiency, Wiskott Aldrich Syndrome, X-linked agammaglobulinemia, and other forms of hypogammaglobulinemia.
The global intravenous immunoglobulin market size was worth US$ XX billion in 2020 and further predicted to reach US$ XX billion by 2027, at a CAGR of XX% during the forecast period (2020-2027).
Factors such as fast changing lifestyles such as sedentary habits, including consumption of salt, sugars and saturated fats, reduced physical activities, and increase in alcohol consumption has led to risinf prevalence of diseases such as acquired and primary immunodeficiency diseases. IVIG therapies being one of the most effective & the only available treatment option for such diseases is anticipated to fuel the intravenous immunoglobulin market growth during the forecast period.
The demand for for the treatment of is rapidly increasing as it is the. The increasing prevalence of lifestyle-associated disorders such as obesity & antibody deficiency disorders are the factors
Increase in primary immune deficiency diseases to drive the intravenous immunoglobulin market
Increasing cases of primary immune deficiency diseases is expected to drive the demand for fast, accurate, and safe treatment options, thus augmenting the market growth. Furthermore, Increasing occorance of dieseases, such as organ transplantation, neurological disorders, peripheral neuropathies, and Alzheimer's disease are expected to provide growth opportunities to the intravenous Immunogl (IVIG) market players. Thus, growing cases of the aforementioned diseases are expected to increase the penetration of IVIG during the forecast period.
Increase in Research and Development
Many companies are actively involved in R&D for the development of innovative drugs and discovering new therapeutic areas for the existing drugs. In August 2017, Kedrion Biopharma, Inc. and Kamada Ltd. received approval from the U.S. FDA for their new product KEDRAB. Promeinent industry players are emphesizing in the development of new plasma collection centers and other collaborative strategies to expand their geographical reach and widen their product portfolio.
COVID-19 Impact Analysis
COVID-19 pandemic affected the global economy in many terms, such as directly affecting production and demand, supply chain disruption, and financial impact. COVID-19 has impacted the manufacturers' supply chain across the globe and shut down the production facilities to minimize the risk of virus spread. Also, the pandemic is expected to have a positive impact on the growth of the intravenous immunoglobulin market globally. The market for immunoglobulin therapies is expected to spike during the pandemic and, thus drive the intravenous immunoglobulin market during the forecast period.
Based on the application, the Intravenous Immunoglobulin market has been classified into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura, inflammatory myopathies, specific antibody deficiency, Guillain-Barre syndrome, and others.
Hypogammaglobulinemia segment is forecasted for largest market share
The hypogammaglobulinemia segment is the highest contributor to the global market, and is anticipated to maintain its dominance throughout the forecast period. This is mainly attributed to a significant rise in the prevalence of hypogammaglobulinemia disorder across the globe over the years.
Chronic Inflammatory demyelinating polyneuropathy (CIDP) segment held significant Market share
Chronic Inflammatory demyelinating polyneuropathy (CIDP) segment held significant market share in the application segment of intravenous immunoglobulin market during the forecast period. It is found in patients with diabetes mellitus. The treatment of CIPD involves the usage of immunosuppressive drugs, plasmapheresis and steroids. IVIG is an effective alternative to these methods. The associated benefits such as safety, minimally invasive and user-friendly treatment option are few other factors contributing towards the development of the industry.
Based on geography, the study analyzes the yeast extract market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.
North America leads the global market throughout the forecast period
North America is expected to maintain its dominance in the global intravenous immunoglobulin market through the forecast period. Increasing healthcare expenditure, increasing level of consciousness for the products involved in the treatment of immunodeficiency disorders, and the rising inclination of clinicians towards immunodeficiency therapies are major factors attributing to the market growth. Additionally, growing occurrences of primary immunodeficiency (PID) are also expected to drive market growth in the North American region.
The Asia Pacific is expected to show significant growth during the forecast period due to the increasing awareness and potential opportunities for the adoption of immunoglobulin-based therapies for the treatment of primary immune deficiencies. Furthermore, the growing geriatric population in the region will augment the market growth.
The global intravenous immunoglobulin market is fiercely competitive with the presence of several large and small players operating in the market. These market players acquire promising companies to expand in the fast-growing markets, focusing on improving their market performance. The key intravenous immunoglobulin players which are contributing to the growth of the global market are Bharat Serums and Vaccines Limited, Biotest AG, China Biologic Products, Inc., Guizhou Taibang Biological Products Co., Ltd, CSL Limited, Grifols, S.A., Hualan Biological Engineering Inc., Kedrion S.p.A., LFB Group, Octapharma AG.
Bharat Serums and Vaccines Limited
Overview: Bharat Serums and Vaccines Limited is one of the fastest growing bio pharmaceutical companies in India. BSV offers products in the areas of gynecology, assisted reproductive technology, critical care, emergency medicine, neurology, nephrology, hematology, and urology. The company provides its products to retail outlets and hospitals through distributors primarily in India, as well as in the Asia Pacific, the Russian Federation, CIS countries, Africa. The Company's specialty is in Injectables, Novel Drug Delivery, R&D, Biologicals, Clinical Research, and Biotech.
Product Portfolio: The company's products portfolio includes plasma derivatives, monoclonals, fertility hormones, antifungals, anaesthetics, cardiovascular drugs, and equine immunoglobulin /antitoxins.
The global intravenous immunoglobulin market report would provide access to an approx. 60 market data table, 72 figures and 270 pages.
LIST NOT EXHAUSTIVE